Regulated expression of the Mac-1, LFA-1, p150,95 glycoprotein family during leukocyte differentiation.
The regulation of Mac-1, LFA-1, and p150,95 expression during leukocyte differentiation was examined. LFA-1 was present on almost all cell types studied. Both Mac-1 and p150,95 were present on the more mature cells of the myelomonocytic series, but only p150,95 was detected on some B cell lines and cloned cytotoxic T lymphocytes. Phorbol myristate acetate (PMA) stimulation of B chronic lymphocytic leukemia cells dramatically increased p150,95 expression. The resultant Mac-1, LFA-1, p150,95 phenotype resembled hairy cell leukemia, a B cell plasmacytoid leukemia. The promonocytic cell line U937 and the promyeloblastic cell line HL-60 expressed only LFA-1. Monocytic differentiation of U937 cells was stimulated by PMA, and induced the concomitant expression of Mac-1 and p150,95, with more p150,95 induced than Mac-1. Granulocyte/macrophage colony-stimulating factor (GM-CSF) stimulation of U937 cells gave similar results. PMA-stimulated monocytic differentiation of the HL-60 cell line also induced expression of both Mac-1 and p150,95. The number of p150,95 molecules on PMA-stimulated U937 and HL-60 cells were 5 X 10(5) and 3 X 10(5), respectively. Retinoic acid stimulated myeloid differentiation of HL-60 cells and induced expression of both Mac-1 and p150,95. These cells acquired a Mac-1, LFA-1, p150,95 profile that resembled that of granulocytes, with more Mac-1 than p150,95 induced. GM-CSF stimulation of HL-60 cells induced a similar Mac-1 and p150,95 phenotype. The contributions of Mac-1, LFA-1, and p150,95 to aggregation of PMA-differentiated U937 cells were assessed. Monoclonal antibodies to the beta subunit and the LFA-1 alpha subunit, but not those to p150,95 or Mac-1 alpha subunit, inhibited this homotypic adherence.
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface / Q000378:metabolism*; D002448:Cell Adhesion; D002449:Cell Aggregation; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D003115:Colony-Stimulating Factors / Q000494:pharmacology; D005434:Flow Cytometry; D006023:Glycoproteins / Q000378:metabolism; D006098:Granulocytes / Q000166:cytology / Q000502:physiology*; D006801:Humans; D007372:Interferons / Q000494:pharmacology; D008214:Lymphocytes / Q000166:cytology / Q000502:physiology*; D009000:Monocytes / Q000166:cytology / Q000502:physiology*; D011951:Receptors, Complement / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D003115:Colony-Stimulating Factors; D006023:Glycoproteins; D011951:Receptors, Complement; D014212:Tretinoin; D007372:Interferons; D013755:Tetradecanoylphorbol Acetate